+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer

Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer

Clinical Cancer Research 8(4): 1054-1060

Determination of meaningful prognostic indicesremains a high priority for women diagnosed with node-negative primary breast cancer. Currently, 30% of these women relapse, and there is no reliable means of predicting this group of patients. This study investigates whether the level of expression of versican, an anticell adhesive proteoglycan, in the peritumoral stromal tissue of women with node-negative, primary breast cancer predicts relapse-free survival. This study also examines whether breast cancer cells regulate the secretion of versican by mammary fibroblasts. Immunoreactive versican was measured in breast cancer tissue sections of 58 node-negative patients by video image analysis. Primary isolates of mammary fibroblasts were cultured in medium conditioned by the breast cancer cell lines ZR-75-1, MCF-7, BT-20, and MB231. Changes in versican secretion were measured by immunoblotting and enhanced chemiluminescence. Cox analyses indicated that peritumoral versican level was the sole predictor of relapse-free survival. The relapse rate in patients with low versican levels was lower than in patients with high versican levels (Kaplan-Meier: 83% relapse free at 5 years for versican mean integrated absorbance <14 versus 33% for > or = 14, P = 0.0006). Accumulation of versican in medium of mammary fibroblasts was increased after culture in conditioned medium from breast cancer cell lines. Relapse in women with node-negative breast cancer is related to the level of versican deposited in peritumoral stroma by mammary fibroblasts. Versican secretion appears to be regulated by breast cancer cell mediators. Neoplastic remodeling of extracellular matrix through increased versican deposition may facilitate local invasion and metastasis.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 047214977

Download citation: RISBibTeXText

PMID: 11948113

Related references

Combination of grading and new biological factors can predict relapse and survival in patients with node-negative primary breast cancer. Onkologie 17(2): 166-172, 1994

Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clinical Cancer Research 14(22): 7452-7460, 2008

Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. American Journal of Pathology 152(3): 721-728, 1998

Tumor angiogenesis in node-negative breast cancer: relationship with relapse free survival. Anticancer Research 16(6c): 4001-4002, 1996

Influence of anemia on local relapse free survival of premenopausal primary breast cancer patients under adjuvant CMF chemotherapy An analysis of the Austrian Breast Cancer Study Group. Breast 12(Suppl. 1): S43, 2003

Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients. Journal of Cancer 8(16): 3122-3129, 2017

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. Bmc Cancer 12: 562, 2013

Histopathological grading of breast specimens correlates with disease free survival in node negative breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 30: 252, 1989

A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial. Annals of Oncology 24(9): 2284-2291, 2014

Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. New England Journal of Medicine 320(10): 627-633, 1989

Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal of Clinical Pathology 146(4): 496-502, 2017

High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer. Oncotarget 9(46): 28131-28140, 2018

Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. Journal of Pathology 193(4): 442-449, 2001

Prevalence of putative breast cancer stem cells (BCSC) in lymph node occult metastases (LNOM) of patients with node-negative (LN-) breast cancer (BC). Journal of Clinical Oncology 26(15_Suppl): 1069-1069, 2016

Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. Tumour Biology 37(7): 9813-9823, 2017